---
title: "Oncotelic Therapeutics delays 2024 annual report"
url: "https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "OTC:OTLC"
source: "https://www.sec.gov/Archives/edgar/data/908259/000164117225001610/formnt10-k.htm"
summary: "The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from t"
---

By the aibio.space news desk.

Sources

- [Oncotelic Therapeutics, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/908259/000164117225001610/formnt10-k.htm)

[OTLC](https://aibio.space/companies/oncotelic-therapeutics/)

2025-03-31

# Oncotelic Therapeutics delays 2024 annual report, expects to file within extension

Tickers [OTLC](https://aibio.space/companies/oncotelic-therapeutics/)

The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.

## Key facts

- **Company**: Oncotelic Therapeutics, Inc. (OTC: OTLC)

- **News type**: Distress

- **Primary source**: [Oncotelic Therapeutics, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/908259/000164117225001610/formnt10-k.htm)

*The Capitol dome seen from below. Photo: U.S. Department of Homeland Security (Source), CC0, via rawpixel. The picture shows the field, not the companies named.*

Oncotelic Therapeutics, Inc. told the SEC that it will not file its annual report on Form 10-K for the period ended December 31, 2024 on time.

The company filed a [Form 12b-25](https://www.sec.gov/Archives/edgar/data/908259/000164117225001610/formnt10-k.htm), the notice used when a periodic report will be late. For an annual report, the notice gives a company up to the fifteenth calendar day after the due date to file.

In the notice, Oncotelic said it is working on, and unable to compile, the necessary financial information required to prepare a complete filing. It said it would be unable to file the annual report in a timely manner without unreasonable effort or expense. The company expects to file within the extension period.

Oncotelic checked boxes stating that it has filed all other periodic reports required during the preceding 12 months. It also said it does not anticipate that its earnings statements will show a significant change in results of operations from the prior fiscal year.

The company was formerly named Mateon Therapeutics, Inc.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

OTLC

Oncotelic Therapeutics, Inc.

OTC · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oncotelic Therapeutics delays 2024 annual report", 2025-03-31, https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/